Zavegepant: meta-analysis of COVID-19 studies

All studies   Mortality   ICU   Serious outcomes   Recovery   RCTs   RCT mortality   All outcomes  
Meta-analysis1 study · 43 patientsc19early.org

Zavegepant for COVID-19

Serious outcome risk
Zavegepant
Control
Outcome (studies)
Improvement
Relative risk · 95% CI
All studies (1)−168%
Mortality (1)−168%
ICU admission (1)−25%
RCTs (1)−168%
Late (1)−168%
00.511.5+
← Zavegepant
reduces riskIncreased
risk →
c19early.org
October 2026

Zavegepant COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Amali (DB RCT)−168%2.68 · 0.34–20.88death5/281/15BHV-3500
Late treatment−168%2.68 · 0.34–20.885/281/15168% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.35
All studies−168%2.68 · 0.34–20.885/281/15168% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.3500.511.52+
Rotate screen for more detailsIncrease width for more details
← Zavegepant
reduces riskZavegepant
increases risk →
c19early.org
October 2026

Zavegepant COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Amali (DB RCT)−168%2.68 · 0.34–20.885/281/15BHV-3500
Late treatment−168%2.68 · 0.34–20.885/281/15168% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.35
All studies−168%2.68 · 0.34–20.885/281/15168% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.3500.511.52+
Rotate screen for more detailsIncrease width for more details
← Zavegepant
reduces riskZavegepant
increases risk →
c19early.org
October 2026

Zavegepant COVID-19 ICU results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Amali (DB RCT)−25%1.25 · 0.38–4.147/283/15BHV-3500
Late treatment−25%1.25 · 0.38–4.147/283/1525% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.73
All studies−25%1.25 · 0.38–4.147/283/1525% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.7300.511.52+
Rotate screen for more detailsIncrease width for more details
← Zavegepant
reduces riskZavegepant
increases risk →
c19early.org
October 2026

Zavegepant COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Amali (DB RCT)−168%2.68 · 0.34–20.88death5/281/15BHV-3500
Late treatment−168%2.68 · 0.34–20.885/281/15168% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.35
All studies−168%2.68 · 0.34–20.885/281/15168% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.3500.511.52+
Rotate screen for more detailsIncrease width for more details
← Zavegepant
reduces riskZavegepant
increases risk →
c19early.org
October 2026

Zavegepant COVID-19 recovery results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Amali (DB RCT)−11%1.11 · 0.84–1.47no recov.20 (n)11 (n)BHV-3500
Late treatment−11%1.11 · 0.84–1.4720 (n)11 (n)11% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.47
All studies−11%1.11 · 0.84–1.4720 (n)11 (n)11% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.4700.511.52+
Rotate screen for more detailsIncrease width for more details
← Zavegepant
reduces riskZavegepant
increases risk →
c19early.org
October 2026

Zavegepant COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Amali (DB RCT)−168%2.68 · 0.34–20.88death5/281/15BHV-3500
Late treatment−168%2.68 · 0.34–20.885/281/15168% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.35
All studies−168%2.68 · 0.34–20.885/281/15168% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.3500.511.52+
Rotate screen for more detailsIncrease width for more details
← Zavegepant
reduces riskZavegepant
increases risk →
c19early.org
October 2026

Zavegepant COVID-19 RCT mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Amali (DB RCT)−168%2.68 · 0.34–20.885/281/15BHV-3500
Late treatment−168%2.68 · 0.34–20.885/281/15168% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.35
All studies−168%2.68 · 0.34–20.885/281/15168% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.3500.511.52+
Rotate screen for more detailsIncrease width for more details
← Zavegepant
reduces riskZavegepant
increases risk →